Latest Articles

Publication Date
Single-cell transcriptomic atlas of different endometriosis indicating that an interaction between endometriosis-associated mesothelial cells (EAMCs) and ectopic stromal cells may influence progesterone resistance.

Endometriosis is a hormone-dependent disease, which can usually be divided into peritoneal endometriosis (PEM), deep-infiltrating endometriosis (DIE) and ovarian endometriosis (OEM). Although the three pathologic types are essentially the same …

Published: Feb. 20, 2025, 12:34 a.m.
Clinical Utility of Serum Dehydroepiandrosterone Sulfate (DHEA-S) and Serum Anti-Mullerian Hormone (AMH) Levels in Infertile Females.

To determine the correlation of serum dehydroepiandrosterone sulphate and anti-mullerian hormone levels with infertility in females.

Published: Feb. 13, 2025, 12:08 a.m.
Efficacy and Safety of Chinese Patent Medicines Combined with Conventional Therapies for Endometriosis: A Systematic Review and Bayesian Network Meta-Analysis.

Conventional hormonal treatments for endometriosis (EMs) are often associated with significant side effects. In recent years, many clinical trials and studies have highlighted the remarkable efficacy of Chinese patent medicines …

Published: Feb. 8, 2025, midnight
Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …

Published: Feb. 6, 2025, midnight
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
The effect of chronic inflammation on female fertility.

Inflammation has key biological roles in the battle against pathogens, and additional key processes in development and tissue homeostasis. However, when inflammation becomes chronic it can become a serious medical …

Published: Feb. 1, 2025, midnight
The effect of dienogest and gonadotropin-releasing hormone agonist on pelvic pain after laparoscopic surgery for endometriosis: An RCT.

Endometriosis is a chronic inflammatory condition associated with debilitating chronic pelvic pain that affects women's quality of life. Several drugs have been used to reduce pain and psychological distress associated …

Published: Jan. 31, 2025, midnight
Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases.

This project developed eligibility criteria for menopausal hormone therapy in patients with medical conditions beyond those published in a previous report. A new consortium of scientific societies coordinated by the …

Published: Jan. 30, 2025, midnight
Rare malignant ovarian tumors: a review.

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known …

Published: Jan. 29, 2025, midnight
Management of Common Benign Gynecologic Diseases in Postmenopausal Women.

This study investigated the impact of menopause on the progression and management of common benign gynecological conditions such as polycystic ovary syndrome, endometriosis, uterine fibroids, and adenomyosis. These conditions often …

Published: Jan. 22, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!